News

AstraZeneca makes savings card for Arimidex users

BY Alaric DeArment

WILMINGTON, Del. Anglo-Swedish drug maker AstraZeneca has created a savings card for users of one of its breast cancer drugs, AstraZeneca said Thursday.

The program, for women Arimidex (anastrozole), is designed to save patients up to $300. The program is tied to copays, so if a patient pays a $75 copay, AstraZeneca will cover $25, or $50 if the patient pays a $100 copay.

Arimidex treats hormone receptor-positive early breast cancer in postmenopausal women.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Pampers by Cynthia Rowley hitting Target shelves in July

BY Allison Cerra

CINCINNATI Pampers has teamed up with renowned fashion designer Cynthia Rowley to bring fashionable diapers to Target shoppers this summer.

Pampers by Cynthia Rowley will be available in 11 colorful styles — for boys and girls — beginning in mid July at Target stores and on Target.com. Pampers by Cynthia Rowley incorporate a beautiful look and feel — giving discerning parents high performance, value and choice of style. The diaper collection, which will be available in pastel designs, including madras, stripes and printed ruffles, is suited specifically to babies and toddlers and delivers the perfect blend of utility and aesthetics.

“Of course parents want the very best for their little ones,” said Jodi Allen, Procter & Gamble’s VP North America baby care. “We also know that sometimes it’s the little things — like how a baby is clothed — that can bring added joy to mom and dad. While performance always comes first, we know that design is also important to parents. We’re pleased to introduce the first diaper line that brings together the best of these two worlds.”

For more information about the new Pampers by Cynthia Rowley collection to be available at Target and Target.com, visit Pampers.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Eisai, SuperGen release data for Dacogen trial

BY Alaric DeArment

DUBLIN, Calif. Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug for leukemia, Eisai’s development partner said Wednesday.

SuperGen said that while the injectable drug Dacogen (decitabine) did not show statistically significant superiority in overall survival in elderly patients with acute myeloid leukemia compared over treatments given to patients in the control group, “a trend was evident.”

Based on findings, Eisai plans to submit a regulatory application to the Food and Drug Administration seeking approval for Dacogen as a treatment for elderly patients with AML. The drug already is approved to treat myelodysplastic syndromes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?